<?xml version="1.0" encoding="UTF-8"?>
<p id="Par34">However, these drugs have not proved enough efficacy in clinical trials. In the case of chloroquine and hydroxychloroquine, although initially was thought to be useful [
 <xref ref-type="bibr" rid="CR114">114</xref>], clinical trials have shown no significant benefits, but significant adverse events associated [
 <xref ref-type="bibr" rid="CR137">137</xref>–
 <xref ref-type="bibr" rid="CR139">139</xref>]. There is insufficient evidence to support the effectiveness or safety of hydroxychloroquine or chloroquine for the treatment of COVID-19 in hospitalized patients as a systematic living review reported [
 <xref ref-type="bibr" rid="CR140">140</xref>, 
 <xref ref-type="bibr" rid="CR141">141</xref>]. In the case of remdesivir, appears to decrease the time to recovery by 2.5 days, but its clinical utility remains to be confirmed [
 <xref ref-type="bibr" rid="CR142">142</xref>–
 <xref ref-type="bibr" rid="CR144">144</xref>]. Remdesivir, chloroquine and hydroxychloroquine though being used in COVID-19 patients under the common emergencies but need to be appropriately evaluated for clinical applications in COVID-19 patients and side effects need to be explored for the safety purposes [
 <xref ref-type="bibr" rid="CR145">145</xref>–
 <xref ref-type="bibr" rid="CR148">148</xref>]. For dexamethasone, considered a boon for COVID-19 patients [
 <xref ref-type="bibr" rid="CR149">149</xref>, 
 <xref ref-type="bibr" rid="CR150">150</xref>] but a trial showed that it reduces mortality only in patients that require oxygen [
 <xref ref-type="bibr" rid="CR151">151</xref>–
 <xref ref-type="bibr" rid="CR153">153</xref>].
</p>
